Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

The average one-year price target for Recursion Pharmaceuticals (NasdaqGS:RXRX) has been revised to $7.14 / share. This is an increase of 10.53% from the prior estimate of $6.46 dated December 3, 2025 ...

However, Recursion’s revenue fell short, reaching only $5.18 million compared to the expected $16.95 million. In another development, Recursion announced the registration of 7.1 million shares for ...

ROCHESTER, N.Y. – It is something we have not seen in a couple of winter seasons. Due to the recent stretch of bitterly cold temperatures, there appears to be a significant amount of ice coverage on ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...

Somewhere at the edge of mathematics lurks a number so large that it breaks the very foundations of our understanding - and ...

The PVP Series was first introduced in Endwalker ’s 6.1 as a better incentive for PVP. The PVP in Final Fantasy XIV is heavily underrepresented purely because very few players interact with it to a ...